Intrexon

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Intrexon and buy or sell other stocks, ETFs, and their options commission-free!

About XON

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. 

CEO
Helen Sabzevari, PhD
CEOHelen Sabzevari, PhD
Employees
160
Employees160
Headquarters
Germantown, Maryland
HeadquartersGermantown, Maryland
Founded
1998
Founded1998
Employees
160
Employees160

XON Key Statistics

Market cap
490.17M
Market cap490.17M
Price-Earnings ratio
-2.94
Price-Earnings ratio-2.94
Dividend yield
Dividend yield
Average volume
8.83M
Average volume8.83M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$5.47
52 Week high$5.47
52 Week low
$1.23
52 Week low$1.23

Stock Snapshot

Intrexon(XON) stock is priced at $1.39, giving the company a market capitalization of 490.17M. It carries a P/E multiple of -2.94.

Intrexon(XON) stock opened on 2026-04-09 at —. The price climbed to — and dipped to —.

The Intrexon(XON)'s current trading volume is 0, compared to an average daily volume of 8.83M.

During the past year, Intrexon(XON) stock moved between $1.23 at its lowest and $5.47 at its peak.

During the past year, Intrexon(XON) stock moved between $1.23 at its lowest and $5.47 at its peak.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.